Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf375 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Hisao Okabe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, Fukushima Medical University, Fukushima City. Hauptthemen laut MEDLINE: Antibodies, Viral, Antibodies, Neutralizing, Viral Fusion Proteins, Respiratory Syncytial Virus, Human. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, JSPS, KAKENHI.
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) fusion protein contains major neutralizing epitopes (sites II, III, IV, V, and Ø), targeted by new vaccines and monoclonal antibodies. However, data on serum epitope-specific antibodies (ESAs) and their association with neutralizing activity (NA) are limited. We aimed to evaluate ESA in healthy Japanese adults and their association with NA against various clinical isolates.
Methods
Serum samples were collected from pediatricians from February to March 2020. ESA and NA levels were quantified by enzyme-linked immunosorbent assays and neutralizing assays. Pearson correlation analysis was used to estimate the association.
Results
Ninety-two healthy adults aged 28 to 75 years were included. The ESA levels differed significantly across all sites. ESA levels were lower at sites IV and Ø (median [IQR], 2.7 μg/mL [2.2–3.4] and 10.2 [8.1–13.5], respectively) than at other sites (41.9 [35.0–56.7] at II, 16.6 [9.4–44.1] at III, and 35.3 [28.4–42.4] at V). Associations between ESA and NA levels differed by subtype and mutation.
Conclusions
ESA and NA levels should be considered in the development and application of vaccines and monoclonal antibody therapies. Monitoring serum ESA levels and RSV fusion protein genes is essential for treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, School of Medicine, Fukushima Medical University, Fukushima City.
- Department of Pediatrics, Hoshi General Hospital, Koriyama City.
- Department of Respiratory Viruses, Japan Institute for Health Security, National Institute of Infectious Diseases, Tokyo.
ORCID-Profile: Hisao Okabe, Koichi Hashimoto, Takashi Ono, Kazuya Shirato
Förderung
- Japan Agency for Medical Research and Development
- JSPS
- KAKENHI
Zitieren
APA
Okabe, H., Hashimoto, K., Norito, S., Ono, T., Asano, Y., Sato, M., Shirota, J., Hiruta, S., Shima, E., Kume, Y., Chishiki, M., Maeda, H., Watanabe, M., Mashiyama, F., Shirato, K., Hosoya, M., & Go, H. (2026). Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf375
Vancouver
Okabe H, Hashimoto K, Norito S, Ono T, Asano Y, Sato M, et al. Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf375
BibTeX
@article{Okabe2026,
author = {Okabe, Hisao and Hashimoto, Koichi and Norito, Sakurako and Ono, Takashi and Asano, Yuichiro and Sato, Masatoki and Shirota, Jun and Hiruta, Shun and Shima, Eriko and Kume, Yohei and Chishiki, Mina and Maeda, Hajime and Watanabe, Masahiro and Mashiyama, Fumi and Shirato, Kazuya and Hosoya, Mitsuaki and Go, Hayato},
title = {Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf375}
}
EUVIMED